

Cara Therapeutics, Inc.  
Form 4  
February 05, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**ALTA BIOPHARMA PARTNERS  
III LP**

(Last) (First) (Middle)

**ONE EMBARCADERO CENTER,  
37TH FLOOR,**

(Street)

**SAN FRANCISCO, CA 94111**

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading  
Symbol  
**Cara Therapeutics, Inc. [CARA]**

3. Date of Earliest Transaction  
(Month/Day/Year)  
**02/05/2014**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

\_\_\_\_ Director \_\_\_\_X\_\_\_\_ 10% Owner  
\_\_\_\_ Officer (give title below) \_\_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_\_X\_\_ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/05/2014		C <sup>(1)</sup>		1,118,675	A	\$ 0	1,118,675	I	See Footnote <u>(2)</u>
Common Stock	02/05/2014		C <sup>(3)</sup>		531,442	A	\$ 0	1,650,117	I	See Footnote <u>(2)</u>
Common Stock	02/05/2014		P		103,330	A	\$ 11	1,753,447	I	See Footnote <u>(2)</u>
Common Stock	02/05/2014		C <sup>(1)</sup>		75,129	A	\$ 0	75,129	I	See Footnote

Edgar Filing: Cara Therapeutics, Inc. - Form 4

Common Stock	02/05/2014	C <sup>(3)</sup>	35,691	A	\$ 0	110,820	I	(4) See Footnote (4)
Common Stock	02/05/2014	P	6,940	A	\$ 11	117,760	I	See Footnote (4)
Common Stock	02/05/2014	C <sup>(1)</sup>	27,568	A	\$ 0	27,568	I	See Footnote (5)
Common Stock	02/05/2014	C <sup>(3)</sup>	13,097	A	\$ 0	40,665	I	See Footnote (5)
Common Stock	02/05/2014	P	2,547	A	\$ 11	43,212	I	See Footnote (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				Code	V (A) (D)	Date Exercisable Expiration Date	Title Amount or Number of Shares
Series C Preferred Stock	(1)	02/05/2014		C	2,363,654	(1) (1)	Common Stock 1,118,67
Series C Preferred Stock	(1)	02/05/2014		C	158,741	(1) (1)	Common Stock 75,129
Series C Preferred Stock	(1)	02/05/2014		C	58,250	(1) (1)	Common Stock 27,568
Series D Preferred Stock	(3)	02/05/2014		C	1,328,604	(3) (3)	Common Stock 531,442

Series D Preferred Stock	(3)	02/05/2014	C	89,227	(3)	(3)	Common Stock	35,691
Series D Preferred Stock	(3)	02/05/2014	C	32,742	(3)	(3)	Common Stock	13,097

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ALTA BIOPHARMA PARTNERS III LP ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		
ALTA BIOPHARMA MANAGEMENT III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		
ALTA BIOPHARMA PARTNERS III GMBH & CO BETEILIGUNGS KG C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		
ALTA EMBARCADERO BIOPHARMA PARTNERS III LLC C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		
CHAMPSI FARAH C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		
HURWITZ EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111	X	X		
PENHOET EDWARD C/O ALTA PARTNERS ONE EMBARCADERO CENTER, 37TH FLOOR SAN FRANCISCO, CA 94111		X		

## Signatures

/s/Darren DeStefano,  
Attorney-in-Fact 02/05/2014

\_\_Signature of Reporting Person

Date

Darren DeStefano,  
Attorney-in-Fact 02/05/2014

## Edgar Filing: Cara Therapeutics, Inc. - Form 4

__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014
__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014
__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014
__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014
__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014
__Signature of Reporting Person	Date
Darren DeStefano, Attorney-in-Fact	02/05/2014

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Series C Preferred Stock held by the reporting persons automatically converted on a 1-for-2.1129 basis into shares of common stock upon the closing of the issuer's initial public offering.  
  
These shares are held of record by Alta BioPharma Partners III, L.P. ("ABP III"). Alta BioPharma Management III, LLC ("ABM III") is the general partner of ABP III. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by ABP III. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.
- (2) The Series D Preferred Stock held by the reporting persons automatically converted on a 1-for-2.5 basis into shares of common stock upon the closing of the issuer's initial public offering.  
  
These shares are held of record by Alta BioPharma Partners III GmbH & Co. Beteiligungs KG ("GmbH"). ABM III is the managing limited partner of GmbH. Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are directors of ABM III and may be deemed to share dispositive and voting power over the shares held by GmbH. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.
- (3) These shares are held of record by Alta Embarcadero BioPharma Partners III, LLC ("Embarcadero"). Edward Hurwitz, a director of the issuer, Farah Champsi and Edward Penhoet are the managers of Embarcadero and may be deemed to share dispositive and voting power over the shares held by Embarcadero. Each of the reporting persons disclaims beneficial ownership of these securities except to the extent of his, her or its respective pecuniary interest therein.

### Remarks:

Please note that all of these reporting persons are no longer subject to Section 16 Form 4 or Form 5 obligations, with the exception of the reporting person who is a director or officer of the issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.